IL6R and cancer: Thus, targeting IL-6 would be a viable strategy to decrease/deplete the level of MDSC in cancer patients to promote the endogenous or induced antitumor immune responses considering that specific antibodies against IL-6 or their ligand IL-6R have been marketed, which needs to be tested in future clinical trials [34, 35].